PressMarch 14, 2024 Clearmind Medicine Obtains Clearance for Its Psychedelic- Based Alcoholism Clinical Trial
PressMarch 14, 2024 ATMA CENA Psychedelic Healthcare Solutions Opens Psychedelic-Assisted Therapy Clinic in Calgary and Provides Update of its Clinic Network
PressMarch 14, 2024 Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
PressMarch 13, 2024 Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
PressMarch 13, 2024 PharmaDrug’s SecureDose Announces Filing of US Provisional Patent for Manufacturing Method for Biosynthetic Pharmaceutical Grade Cocaine
PressMarch 13, 2024 Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
PressMarch 13, 2024 Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
PressMarch 12, 2024 Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study
PressMarch 11, 2024 Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division
Market ResearchMarch 11, 2024 Cleveland Clinic Launches Nationwide Clinical Trial for Magic Mushrooms
PressMarch 8, 2024 Red Light Holland Commences Experimental Research on Psilocybin Truffles to Develop Process for Commercial Manufacturing of Natural-Source Active Pharmaceutical Ingredient
PressMarch 7, 2024 MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
PressMarch 5, 2024 MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomized Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder
